CTCL definition
Examples of CTCL in a sentence
Overtime and flextime conditions are specified in the Site Procedures on the CTCL intranet.
No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Adcetris®) NHSE Treating CD30-positive cutaneous T- cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service.
Development funding by Mundipharma will support jointly agreed-upon clinical development activities, including, but not limited to, the planned Phase 3 studies of FOLOTYN in previously undiagnosed PTCL and in combination with bexarotene in relapsed or refractory cutaneous T-cell lymphoma (CTCL).
In June 1995, the Company notified the FDA that it had submitted incorrect efficacy data to the FDA pertaining to its Phase II dose-ranging studies of BCX-34 for CTCL and psoriasis.
In June 1996, the FDA inspected the Company and one of its clinical sites in relation to Phase II dose-ranging studies of BCX-34 for CTCL and psoriasis, each of which was concluded in early 1995.
Except to the extent prohibited by Applicable Law, promptly after Eisai files the BLA for the Existing Licensed Product for the CTCL Indication in the United States, Eisai shall transfer to the Licensee or its designated Affiliate the original version (or, where the transfer of the original version is prohibited by Applicable Law, a copy) of all such books and records that relate to the CMC Development Activities and the ‘302 Development Activities (except that Eisai may retain a copy of the same).
Subject to Eisai’s performance of the ‘302 Development Activities and the CMC Development Activities, Licensee shall use Commercially Reasonable Efforts to Develop a Licensed Product for the United States for the CTCL Indication.
The Organization can use the Contribution as the organissation finds relevant to create awareness of Cutaneous T-cell lymphoma (CTCL) (the “Purpose”).
In addition, it is possible that other competitors of the Company could obtain orphan drug designation for product candidates that are not the same as BCX-34 though they are intended for use to treat CTCL.
In October 1993, the Company obtained from the FDA an orphan drug designation for BCX-34 to treat CTCL, and may request orphan drug designation for more of its products and/or additional indications as part of its overall regulatory strategy in the future.